Startup ArtiQ announces that it has obtained CE marking for ArtiQ.PFT, a software using artificial intelligence (AI) for automated interpretation of pulmonary function tests (PFTs) to support diagnosis of lung diseases.
The software automates report writing, allowing doctors to spend more time with their patients and ensuring all reports are according to the latest international standards. Additionally, the software predicts the probability of lung diseases almost twice as accurately as a pulmonologist. This holds the potential to come to a final diagnosis with fewer additional tests.
The CE marking allows ArtiQ to bring ArtiQ.PFT to hospitals in Europe. This is in line with the company's plan to deploy the technology in multiple Belgian centers in the coming months and expand internationally quickly after.
"Obtaining the CE mark is an essential milestone in following our strategy to bring ArtiQ.PFT to the market and support doctors in the diagnosis, treatment and monitoring of respiratory diseases," says Marko Topalovic, CEO and co-founder of ArtiQ, “In the next year, we will not only build the European market, but also start preparing to expand to other markets such as the US.”